Cargando…
Dapagliflozin alleviates renal fibrosis in a mouse model of adenine-induced renal injury by inhibiting TGF-β1/MAPK mediated mitochondrial damage
Renal fibrosis is a common pathological outcome of various chronic kidney diseases, and as yet, there is no specific treatment. Dapagliflozin has shown renal protection in some clinical trials as a glucose-lowering drug, but its role and mechanism on renal fibrosis remain unclear. In this study, we...
Autores principales: | Zeng, Jianhua, Huang, Hao, Zhang, Yan, Lv, Xin, Cheng, Jiawei, Zou, Si Jue, Han, Yuanyuan, Wang, Songkai, Gong, Li, Peng, Zhangzhe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028454/ https://www.ncbi.nlm.nih.gov/pubmed/36959860 http://dx.doi.org/10.3389/fphar.2023.1095487 |
Ejemplares similares
-
Fluorofenidone Alleviates Renal Fibrosis by Inhibiting Necroptosis Through RIPK3/MLKL Pathway
por: Dai, Qin, et al.
Publicado: (2020) -
Dapagliflozin Alleviates Renal Fibrosis by Inhibiting RIP1-RIP3-MLKL-Mediated Necroinflammation in Unilateral Ureteral Obstruction
por: Xuan, Mei Ying, et al.
Publicado: (2022) -
Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition
por: Chen, Weixiang, et al.
Publicado: (2023) -
Fluorofenidone Inhibits UUO/IRI-Induced Renal Fibrosis by Reducing Mitochondrial Damage
por: Liao, Xiaohua, et al.
Publicado: (2022) -
Dapagliflozin Attenuates Myocardial Fibrosis by Inhibiting the TGF-β1/Smad Signaling Pathway in a Normoglycemic Rabbit Model of Chronic Heart Failure
por: Chen, Xuefeng, et al.
Publicado: (2022)